Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Phenotype-genotype correlations and the efficacy of growth hormone treatment in Korean children with Prader-Willi syndrome

프래더 윌리 증후군의 유전학적 발병 기전에 따른 표현형 및 성장 호르몬 치료 효과에 관한 연구

  • Bae, Keun Wook (Department of Pediatrics, Asan Medical Center University of Ulsan College of Medicine) ;
  • Ko, Jung Min (Department of Pediatrics, Asan Medical Center University of Ulsan College of Medicine) ;
  • Yoo, Han Wook (Medical Genetics Clinic and Laboratory, Asan Medical Center University of Ulsan College of Medicine)
  • 배근욱 (울산대학교 의과대학 서울아산병원 소아청소년과) ;
  • 고정민 (울산대학교 의과대학 서울아산병원 소아청소년과) ;
  • 유한욱 (울산대학교 의과대학 서울아산병원 의학유전학 클리닉)
  • Received : 2007.09.03
  • Accepted : 2007.10.18
  • Published : 2008.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Prader-Willi syndrome (PWS) is a complex genetic disorder, caused by the deletion of the paternally derived 15q11-13 region or the maternal uniparental disomy of chromosome 15 (mUPD(15)). In this study, we compared phenotypic differences between those patients whose disease was caused by microdeletion and those caused by mUPD(15). In addition, a comparison of the efficacy of growth hormone (GH) therapy between these two PWS genotypes was analyzed. Methods : Fifty-three patients were diagnosed as having PWS based on molecular and cytogenetic analyses and clinical features. Data that included maternal age, birth weight, a feeding problem in the neonatal period, cryptorchidism, developmental delay or mental retardation, short stature, hypopigmentation, changes in height, weight, and body mass indexes (BMI) before and after GH treatment were obtained by a retrospective review of medical records. The data from the patients with microdeletion were compared with those from the patients with mUPD(15). Results : Of the 53 patients with genetically confirmed PWS, 39 cases had microdeletion and 14 mUPD(15). Maternal ages were significantly higher in the mUPD(15) group, and hypopigmentation and a feeding problem in the neonatal period were more frequent in the microdeletion group. Growth hormone was administered to 20 patients [14 with microdeletion, 6 with mUPD(15)]. There were no differences between the two groups in height velocity, weight and height SDS, and BMI after GH therapy. Conclusion : Phenotype and genotype correlations were observed in Korean PWS patients, such as more advanced maternal ages in the mUPD(15) group and more feeding problems and hypopigmentations in the microdeletion group. Further long-term prospective studies are needed to correlate other aspects of the phenotypes.

목 적 : PWS의 두 가지 대표적 유전형인 미세결실형과 mUPD (15)형에서, 유전형에 따른 표현형의 차이와 성장 호르몬 투여 효과의 차이를 비교해 보고자 하였다. 방 법 : 1990년 1월부터 2007년 1월까지 서울아산병원에서 15번 염색체의 미세 결실에 대한 FISH 검사 및 메틸화-특이 PCR 검사를 통해 PWS로 확진된 53명의 환자를 대상으로 하였다. 출생시 부모의 연령, 출생 체중, PWS의 주요 표현형인 신생아 시기의 저긴장증, 수유 문제, 남아의 경우 잠복 고환, 발달 지연 및 정신 지체, 저신장, 저색소증, 사시, 척추측만증 등의 유무, 성장 호르몬 치료 전과 치료 후의 신장, 체중, 체질량 지수의 변화를 조사하였고 미세결실형 군과 mUPD(15)형 군으로 나누어 유전형에 따른 차이를 분석하였다. 결 과 : 유전학적 검사상 53명의 대상 환아 모두 미세결실형 또는 mUPD(15)형으로 진단되었으며, 미세결실형은 39명, mUPD (15)형은 14명이었다. 평균 진단 연령은 $4.51{\pm}5.19$세였다. 출생 당시 부모의 연령은 mUPD(15)형 군에서 유의하게 높았으며(P=0.0001), 저색소증(P=0.0001)과 신생아기의 수유 부전(P=0.049)은 미세결실형에서 유의하게 많았으나, 그 외의 조사된 표현형에서는 두 군 간에 통계적으로 의미 있는 차이는 없었다. 성장 호르몬은 20명의 환아[미세결실형 14명, mUPD(15)형 6명]에게 평균 $27.9{\pm}11.9$개월 동안 투여되었다. 두 유전형 간에 성장 호르몬 치료 전 및 치료 후의 신장 SDS, 체중 SDS, 체질량지수, IGF-1, IGFBP3, 신장 증가 속도, 체중 증가 속도의 값에는 의미 있는 차이가 없었다. 결 론 : PWS의 주요한 두 유전형의 비교에서, 부모의 연령은 mUPD(15)형에서 의미 있게 높았으며 신생아기 수유 부전과 저색소증은 결실형에서 의미 있게 많았다. 성장 호르몬의 치료 효과에서는 두 유전형 간에 의미 있는 반응의 차이는 없었다. 향후 두 유전자형과 다른 표현형들(예를 들면 행동, 발달, 지능 등) 과의 연관성에 관한 전향적 연구가 더 필요할 것으로 생각된다.

Keywords

References

  1. Prader A, Labhart A, Willi H. Ein syndrom von Adipositias, Kleinwuchs, Kryptorchismus und Oligophrenie nach myoto-nieartigem Zustandim Neugeborenenalter. Schweiz Med Wochenschr 1956;86:1260-1
  2. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993;91:398-402
  3. Gunay-Aygun M, Schwartz S, Heeger S, ORiordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001;108:E92 https://doi.org/10.1542/peds.108.5.e92
  4. Grugni G, Guzzaloni G, Moro D, Bettio D, De Medici C, Morabito F. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome. Clin Endocrinol (Oxf ) 1998;48:769-75 https://doi.org/10.1046/j.1365-2265.1998.00435.x
  5. Thacker MJ, Hainline B, St Dennis-Feezle L, Johnson NB, Pescovitz OH. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm Res 1998; 49:216-20 https://doi.org/10.1159/000023174
  6. Swaab DF. Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl 1997;423:50-4
  7. Goldstone AP. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 2004;15:12-20 https://doi.org/10.1016/j.tem.2003.11.003
  8. Nativio DG. The genetics, diagnosis, and management of Prader-Willi syndrome. J Pediatr Health Care 2002;16:298-303 https://doi.org/10.1016/S0891-5245(02)00064-0
  9. Paterson WF, Donaldson MD. Growth hormone therapy in the Prader-Willi syndrome. Arch Dis Child 2003;88:283-5 https://doi.org/10.1136/adc.88.4.283
  10. Cassidy SB, Schwartz S. Prader-Willi and Angelman syndromes: disorders of genomic imprinting. Rev Mol Med 1998;77:140-51 https://doi.org/10.1097/00005792-199803000-00005
  11. Gillessen-Kaesbach G, Robinson W, Lohmann D, KayaWesterloh S, Passarge E, Horsthemke B. Genotype-phenotype correlation in a series of 167 deletion and non-deletion patients with Prader-Willi syndrome. Hum Genet 1995;96:638-43 https://doi.org/10.1007/BF00210291
  12. Mitchell J, Schinzel A, Langlois S, Gillessen-Kaesbach G, Schuffenhauer S, Michaelis R, et al. Comparison of phenotype in uniparental disomy and deletion Prader-Willi syndrome: sex specific differences. Am J Med Genet 1996;65:133-6 https://doi.org/10.1002/(SICI)1096-8628(19961016)65:2<133::AID-AJMG10>3.0.CO;2-R
  13. Cassidy SB, Forsythe M, Heeger S, Nicholls RD, Schork N, Benn P, et al. Comparison of phenotype between patients with Prader-Willi syndrome due to deletion 15q and uniparental disomy 15. Am J Med Genet 1997:68;433-40 https://doi.org/10.1002/(SICI)1096-8628(19970211)68:4<433::AID-AJMG12>3.0.CO;2-T
  14. Gunay-Aygun M, Heeger S, Schwartz S, Cassidy SB. Delayed diagnosis in patients with Prader-Willi syndrome due to maternal uniparental disomy 15. Am J Med Genet 1997:71;106-10 https://doi.org/10.1002/(SICI)1096-8628(19970711)71:1<106::AID-AJMG19>3.0.CO;2-Q
  15. Dykens EM, Cassidy SB, King BH. Maladaptive behavior differences in Prader-Willi syndrome due to paternal deletion versus maternal uniparental disomy. Am J Ment Retard 1999;104:67-77 https://doi.org/10.1352/0895-8017(1999)104<0067:MBDIPS>2.0.CO;2
  16. Roof E, Stone W, MacLean W, Feurer ID, Thompson T, Butler MG. Intellectual characteristics of Prader-Willi syndrome: comparison of genetic subtypes. J Intellect Disabil Res 2000:44:25-30 https://doi.org/10.1046/j.1365-2788.2000.00250.x
  17. Webb T, Whittington J, Clarke D, Boer H, Butler J, Holland A. A study of the influence of different genotypes on the physical and behavioral phenotypes of children and adults ascertained clinically as having PWS. Clin Genet 2002;62: 273-81 https://doi.org/10.1034/j.1399-0004.2002.620404.x
  18. Milner KM, Craig EE, Thompson RJ, Veltman MW, Thomas NS, Roberts S, et al. Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype. J Child Psychol Psychiatry 2005:46:1089-96 https://doi.org/10.1111/j.1469-7610.2005.01520.x
  19. Varela MC, Kok F, Setian N, Kim CA, Koiffmann CP. Impact of molecular mechanisms, including deletion size, on Prader-Willi syndrome phenotype: study of 75 patients. Clin Genet 2005;67:47-52 https://doi.org/10.1111/j.1399-0004.2005.00377.x
  20. Torrado M, Araoz V, Baialardo E, Abraldes K, Mazza C, Krochik G, et al. Clinical-etiologic correlation in children with Prader-Willi syndrome (PWS): an interdisciplinary study. Am J Med Genet A 2007;143:460-8
  21. Kim DS, Shin YL, Ko TS, Seo EJ, Y 00 HW. A study of Prader-Willi syndrome and Angelman syndrome with the deletion of same loci in 15 chromosome. J Korean Child Neurol Soc 2002;10:226-34
  22. Lee JE, Moon KB, Hwang JH, Kwon EK, Kim SH, Kim JW, et al. Clinical characteristics and genetic analysis of Prader-Willi syndrome. J Korean Pediatr Soc 2002:45:1126-33
  23. Robinson WP, Bottani A, Xie YG, Balakrishman J, Binkert F, Marhler M, et al. Molecular, cytogenetic, and clinical investigations of Prader-Willi syndrome patients. Am J Hum Genet 1991;49:1219-34
  24. Ginsburg C, Fokstuen S, Schinzel A. The contribution of uniparental disomy to congenital development defects in children born to mothers at advanced childbearing age. Am J Med Genet 2000;95:454-60 https://doi.org/10.1002/1096-8628(20001218)95:5<454::AID-AJMG9>3.0.CO;2-O
  25. Gardner JM, Nakatsu Y, Gondo Y, Lee S, Lyon MF, King RA, et al. The mouse pink-eyed dilution gene: association with human Prader-Willi and Angelman syndromes. Science 1992;257:1121-4 https://doi.org/10.1126/science.257.5073.1121
  26. Rinchik EM, Bultman SJ, Horsthemke B, Lee ST, Strunk KM, Spritz RA, et al. A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. Nature 1993;361:72-6 https://doi.org/10.1038/361072a0
  27. Miller SP, Riley P, Shevell MI. The neonatal presentation of Prader-Willi syndrome revisited. J Pediatr 1999;134:226-8 https://doi.org/10.1016/S0022-3476(99)70420-8
  28. Shin HJ, Kim DH. Effects of growth hormone therapy in Prader-Willi syndrome. J Korean Soc Pediatr Endocrinol 2000;5:52-9
  29. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-5 https://doi.org/10.1210/jc.87.4.1581
  30. Obata K, Sakazume S, Yoshino A, Murakami N, Sakuta R. Effects of 5 years growth hormone treatment in patients with Prader-Willi syndrome. J Pediatr Endocrinol Metab 2003;16:155-62
  31. Park JE, Lee SW, Song KE, Lee HS, Kim DJ, Chung YS, et al. Growth hormone treatment in Prader-Willi syndrome. J Korean Soc Endocrinol 2006;21:40-6 https://doi.org/10.3803/jkes.2006.21.1.40
  32. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr 2004;145:744-9 https://doi.org/10.1016/j.jpeds.2004.08.002
  33. Eiholzer U, Lallemand D, Schlumpf M, Rousson V, Gasser T, Fusch C. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediatr 2004;144:753-8
  34. Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A 2007;143:443-8

Cited by

  1. Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial vol.14, pp.1, 2019, https://doi.org/10.1186/s13023-019-1195-1